Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...
A Phase 1 trial testing RAG-17, a potential ALS therapy for people carrying SOD1 mutations, has dosed its first participant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback